RecruitingEarly phase 1NCT03719105
Blood
Extranodal nasal NK/T cell lymphoma
24
studies recruiting now
as of 7 Sept 2026
294
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
27 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT07727083
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
RecruitingPhase 3NCT07678229
BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
RecruitingNCT01137825
Registry of Older Patients With Cancer
RecruitingPhase 1 / Phase 2NCT07502768
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 24 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Extranodal nasal NK/T cell lymphoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Extranodal nasal NK/T cell lymphoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
17 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Selinexor (Nexpovio)
Phase 2Tofacitinib
Phase 2Tislelizumab (Tevimbra)
Phase 2Camrelizumab
Phase 2Dexamethasone (Aeroseb-dex)
Phase 2Etoposide (Etoposide)
Phase 2Azacitidine (Azacitidine)
Phase 2Cisplatin (Cisplatin)
+ 9 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).